QR kód

Complete response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation

Metastatic pancreatic cancer (mPC) is usually diagnosed at an advanced stage, and systemic therapy is still the main treatment option. Pathological germline mutations in the BRCA1 or BRCA2 genes are present in aroun 4–7% of cases of pancreatic cancer (PC). The poly(adenosine diphosphate-ribose) poly...

Celý popis

Uloženo v:
Hlavní autoři: Agata I. Adamczuk-Nurzyńska, Paweł Nurzyński, Artur Sankowski
Médium: Artigo
Jazyk:Inglês
Vydáno: Via Medica 2026-10-01
Edice:Oncology in Clinical Practice
Témata:
pancreatic cancer
PARP inhibitor
targeted therapy
olaparib
case report
On-line přístup:https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/106789
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky